The ability of Mylan to raise EpiPen’s list price by nearly 550% over the past eight years underscores the pricing power drug companies enjoy for iconic brands facing little competition.
WSJ.com: Health, Wall Street Journal: Business: Health
Thu, 08/25/2016 - 7:47pm